CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive it has filed for Breakthrough Therapy designation with the FDA for the use of its lead drug leronlimab as an adjuvant therapy for the treatment of metastatic triple-negative breast cancer (mTNBC). What's more, Pourhassan commented on recent interaction with potential investors from the Biotech Showcase 2020 in San Francisco.
Full interview: CytoDyn files for breakthrough therapy status in metastatic triple-negative breast cancer
Quick facts: CytoDyn Inc.
Price: 5.2 USD
Market Cap: $3.11 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE